Strategy Notes
YC invests in pre-seed AI/biotech at the right stage, but is US-centric (relocation required) and provides dilutive equity, not non-dilutive grants. The applicant's EU-first strategy and preference for European partners (Servier, Paris-Saclay) suggest EU-based accelerators are higher-priority targets.